Heterocyclyl benzoylguanidine, process of its preparation and pharmaceutical preparation containing thereof

In the present invention there is disclosed a heterocyclylbenzoyl guanidine of the general formula I, in which Re1 represents A, CFi3, CHi2F, CHFi2, Ci2Fi5, CN, NOi2, Hal, C=CH or -X-Re4, Re2 and Re3 represent independently on each other hydrogen Hal, A, -Y-Re4, CN, NOi2, CFi3, CHi2F, CHFi2, Ci2Fi5, CHi2CFi3, -SOin-Re6 or -SOi2NRe4Re5, Ph or OPh, Re5H, A cycloalkyl containing 5 to 7 carbon atoms cycloalkyl methyl containing 6 to 8 carbon atoms in the cycloalkyl moiety, Cfi3, CHi2F, CHFi2, CHi2CFi3, Ph or -CHi2-Ph, Re5H or A, however Re4 and Re5 together form also alkylene containing 4 to 5 carbon atoms, whereby one CHi2 group can also be substituted with oxygen, sulfur, NH, N-A or N-CHi2-Ph, Re6A or Ph, Het imidazolyl, piperidinyl, pyrazolyl, dihydropyridyl, pyrrolyl, benzimidazolyl or furanyl being optionally substituted with 1 or 2 substituents that are selected from a group comprising OH, NHi2, A and/or an oxo group, alkyl containing 1 to 6 carbon atoms, Hal fluorine, chlorine, bromine or iodine, XO, sulfur or NRe5, Ph phenyl being optionally substituted with one, two or three substituents that are selected from a group comprising A, OA, NRe4Re5, fluorine, chlorine, bromine, iodine or trifluoromethyl, n is 1 or 2, as well as physiologically acceptable salts. All the aforementioned compounds exhibit anti-arrhythmic properties and act as inhibitors of cellular Nae+/He+ antiporter.